SuperworthHalozyme Therapeutics profit margin HALO
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 24.9%
- Operating margin, 12 months
- 35.9%
- Net margin on a year earlier
- −22.4 pts
- Peer median
- 24.3%
Over the twelve months to Jun 30, 2026, Halozyme Therapeutics kept 24.9% of its revenue as net profit, with an operating margin of 35.9% and a gross margin of 82.4%.
Five years earlier its net margin was 55.4%.
The median for 10 biotech stocks of a similar size is 24.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 22.7% | 33.6% | 83.6% |
| FY2024 | 43.7% | 54.3% | 84.3% |
| FY2023 | 34.0% | 40.7% | 76.8% |
| FY2022 | 30.6% | 40.5% | 78.9% |
| FY2021 | 90.8% | 62.2% | 81.6% |
| FY2020 | 48.2% | 53.9% | 83.8% |
| FY2019 | −36.9% | −34.5% | 76.8% |
| FY2018 | −52.9% | −45.7% | 93.3% |
| FY2017 | 19.9% | 25.6% | n/a |
| FY2016 | −70.2% | −56.7% | n/a |
| FY2015 | −23.9% | −20.3% | n/a |
| FY2014 | −90.8% | −83.7% | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | −35.2% | −35.4% | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 24.9% | −22.4 pts | 35.9% | |
| Q1 FY26 | 23.1% | −21.6 pts | 33.9% | |
| Q4 FY25 | 22.7% | −21.0 pts | 33.6% | |
| Q3 FY25 | 47.9% | +6.5 pts | 59.3% | |
| Q2 FY25 | 47.3% | +8.7 pts | 57.9% | |
| Q1 FY25 | 44.8% | +7.8 pts | 55.1% | |
| Q4 FY24 | 43.7% | +9.8 pts | 54.3% | |
| Q3 FY24 | 41.4% | +8.9 pts | 50.4% | |
| Q2 FY24 | 38.6% | +8.4 pts | 46.0% | |
| Q1 FY24 | 36.9% | +11.2 pts | 44.0% | |
| Q4 FY23 | 34.0% | +3.3 pts | 40.7% | |
| Q3 FY23 | 32.5% | −3.9 pts | 39.8% |
Against its peers
Companies in Biotechnology nearest Halozyme Therapeutics' size, closest first, today.
| Company | Profit margin |
|---|---|
| HALOHalozyme Therapeutics | 24.9% |
| NBIXNeurocrine Biosciences | 20.9% |
| EXELExelixis | 35.3% |
| TECHBIO-TECHNE | 15.0% |
| RGENRepligen | 5.3% |
| KRYSKrystal Biotech | 54.8% |
| INCYIncyte | 27.7% |
| UTHRUnited Therapeutics | 41.6% |
| ALNYAlnylam Pharmaceuticals | 16.8% |
| ONCBeOne Medicines | 10.7% |
| REGNRegeneron Pharmaceuticals | 27.9% |
| Peer median | 24.3% |
Where Halozyme Therapeutics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Halozyme Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.